Substance / Medication

Bamlanivimab

Overview

Active Ingredient
bamlanivimab
RxNorm CUI
2463114

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bamlanivimab plus etesevimab treatment have a better outcome against COVID-19: A meta-analysis.
Xiang Huai-Rong, He Bei, Li Yun et al. · J Med Virol · 2022
PMID: 34936121Meta-Analysis
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.
Chew Kara W, Moser Carlee, Daar Eric S et al. · Nat Commun · 2022
PMID: 35995785RCTFull text (PMC)
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Choudhary Manish C, Chew Kara W, Deo Rinki et al. · Nat Microbiol · 2022
PMID: 36289399RCTFull text (PMC)
First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
Chen Peter, Datta Gourab, Grace Li Ying et al. · Clin Pharmacol Ther · 2021
PMID: 34455583RCTFull text (PMC)
Impact of early versus late administration of bamlanivimab on readmissions in patients with high-risk COVID-19.
Melton James D, Wilson Kayla, Blind Fred et al. · Am J Emerg Med · 2021
PMID: 34487951ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Bamlanivimab (substance)
SNOMED CT
1119336002
UMLS CUI
C5421805
RxNorm CUI
2463114

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.